Text size :

Drugs, Prix Galien Italia to Servier for oral targeted therapy against gliomas (2)

ADNKRONOS

November 4, 2026

(Adnkronos Health) – The clinical benefit of vorasidenib – the note details – was evaluated in the international phase 3 Indigo study, a multicenter, randomized, double-blind, placebo-controlled trial, conducted in patients with Idh-mutated grade 2 glioma who had undergone at least one surgical intervention and did not immediately require chemotherapy or radiotherapy. The study demonstrated a statistically significant and clinically relevant improvement in progression-free survival (Pfs) compared to placebo, with a 65% reduction in the risk of progression or death. The delay in progression also postponed the initiation of subsequent therapy, as evidenced by the key secondary endpoint Time To Next Intervention (Ttni), which was significantly better with vorasidenib: at 2 years, 80.3% of patients in the experimental arm had not required further interventions, compared to 41.4% in the placebo group.

“From the results of the Indigo study – Simonelli emphasizes – one of the elements that make vorasidenib an innovative therapy clearly emerges: the ability to slow down disease progression and delay the use of radiotherapy and chemotherapy, effective treatments, but burdened by toxicities whose long-term impact is particularly relevant for often young patients with a prolonged life expectancy. Vorasidenib therefore offers the possibility to postpone these treatments, potentially contributing to preserving patients’ cognitive functions, autonomy, and quality of life for longer. Available data also suggest a favorable effect on the control of epileptic seizures, one of the most frequent and debilitating symptoms of the disease.”

The introduction of a therapy targeting Idh mutations therefore marks a change in the therapeutic approach to Idh-mutated grade 2 gliomas, after about twenty years without substantial therapeutic innovations for these patients. “There are scientific milestones that represent much more than a therapeutic advancement: they mark the beginning of a new phase in the history of a disease. This is what is happening today for low-grade Idh-mutated gliomas, where precision medicine is opening up prospects for patients that were hardly imaginable until a few years ago,” states Emilio Gagliardi, Managing Director Servier Italia & Malta. “The awarding of the Prix Galien Italia to vorasidenib – he adds – represents a particular source of pride for Servier and testifies to the increasingly central role that oncology and neurosciences are assuming in our vision of future medicine. Our ambition is to continue exploring new therapeutic possibilities, especially in rare and complex diseases, with the awareness that behind every diagnosis there are people, families, and life projects. It is to this dimension that we want to give value, making patient centrality the principle that guides our path of development and innovation.”

Jiji Press

Related

Page TOP